Abeona Q3 net loss $9.5M; Phase 3 EB-101 meets endpoints, BLA submission planned Q2 2023

ABEONA THERAPEUTICS INC.

2023-Q3 EPS reported -$6.05 revenue$1,346,000

Net loss of $9.5M ($1.48 loss per share) for Q3 2022, compared to $7.0M loss in Q3 2021.
Cash, equivalents and investments totaled $23.5M at Sept 30, 2022; subsequent $35M private placement extends runway into Q3 2024.
Phase 3 VIITAL trial of EB-101 for RDEB met both co-primary endpoints with statistically significant wound healing and pain reduction.
Company plans to submit BLA to FDA for EB-101 in Q2 2023; possible Priority Review Voucher eligibility upon approval.
R&D expenses decreased to $5.5M from $9.1M year-over-year; G&A expenses down to $3.9M from $5.8M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ABEONA THERAPEUTICS INC. reported third quarter of 2022 results: net income $9.5 million, EPS $1.48 loss per common share.

Period: third quarter of 2022
Net income: $9.5 million
EPS: $1.48 loss per common share
Result: reported results

Exact text from the filing

Net loss attributable to common shareholders for the third quarter of 2022 was $9.5 million, or $1.48 loss per common share as compared to $7.0 million, or $1.80 loss per common share, in the third quarter of 2021.

View on SEC.gov

52 earnings releases filed in the last 30 days. Browse all earnings releases →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-22-031599

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.